24 terminated. 24 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Terminated 24 |
| Phase 1 | 7 | Terminated 7 |
Follow Blast Crisis: new trials by email Literature Review of Blast Crisis trials Research Report on Blast Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Dasatinib, Decitabine - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 32 | 2012-06-12 | 2020-10-22 |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies rasburicase, allopurinol - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Terminated | Roswell Park Cancer Institute | 24 | 2011-09-29 | 2018-01-09 |
| Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation anti-thymocyte globulin, rituximab, sirolimus - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 4 | 2010-08-01 | 2019-03-26 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer alemtuzumab, busulfan, cyclophosphamide - Graft Versus Host Disease, Leukemia | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2007-09-01 | 2017-05-24 |
| Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer busulfan, etoposide, intensity-modulated radiation therapy - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 25 | 2007-06-11 | 2023-11-30 |
| Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase LBH589 - Leukemia, Myeloid, Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 27 | 2007-02-23 | 2021-07-15 |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases muromonab-CD3, natural killer cell therapy, fludarabine phosphate - Graft Versus Host Disease, Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2006-12-01 | 2017-05-24 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer anti-thymocyte globulin, fludarabine phosphate, Melphalan - Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | Northside Hospital, Inc. | 5 | 2006-06-01 | 2012-03-23 |
| Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, busulfan - Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 200 | 2006-02-01 | 2017-09-27 |
| Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers. aldesleukin, filgrastim, natural killer cell (NK) therapy - Leukemia, Myelodysplastic Syndromes | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 16 | 2006-02-01 | 2017-12-28 |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Homoharringtonine, Imatinib Mesylate - Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase | Phase 2 | Terminated | ChemGenex Pharmaceuticals | 15 | 2005-10-01 | 2015-01-15 |
| Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease anti-thymocyte globulin, fludarabine phosphate, thiotepa - Leukemia, Myelodysplastic Syndromes | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 24 | 2005-07-01 | 2017-12-28 |
| Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer umbilical cord blood transplantation - Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 12 | 2005-06-01 | 2017-12-28 |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer alemtuzumab, graft-versus-tumor induction therapy, rituximab - Leukemia, Lymphoma | Phase 2 | Terminated | Northside Hospital, Inc. | 36 | 2005-05-01 | 2013-12-18 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2002-09-01 | 2017-02-15 |
| Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia bevacizumab, idarubicin, cytarabine - Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Terminated | National Cancer Institute (NCI) | 60 | 2001-07-01 | 2013-01-23 |
Showing 20 of 24. Sign in to see all of them.
Leukemia (16) · Leukemia, Myeloid, Acute (16) · Leukemia, Myeloid, Accelerated Phase (15) · Congenital Abnormalities (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Myelodysplastic Syndromes (11) · Leukemia, Myeloid, Chronic-Phase (10) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma, Follicular (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Mantle-Cell (8) · Lymphoma, Non-Hodgkin (8) · Burkitt Lymphoma (7) · Leukemia, Myelomonocytic, Chronic (7)
Bone Marrow Diseases (24) · Carcinogenesis (24) · Cell Transformation, Neoplastic (24) · Chronic Disease (24) · Disease Attributes (24) · Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Neoplastic Processes (24) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Leukemia, Myeloid (23) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (18) · Myeloproliferative Disorders (17)
fludarabine phosphate (8) · Cyclophosphamide (7) · Antilymphocyte Serum (6) · Busulfan (6) · Peripheral Blood Stem Cell Transplantation (6) · Tacrolimus (6) · Methotrexate (5) · Cord Blood Stem Cell Transplantation (4) · Cyclosporine (4) · Methylprednisolone (4) · Mycophenolic Acid (4) · Rituximab (4) · Whole-Body Irradiation (4) · Radiotherapy (3) · Thiotepa (3)
Fred Hutchinson Cancer Center (3) · Masonic Cancer Center, University of Minnesota (3) · City of Hope Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Northside Hospital, Inc. (2) · Barbara Ann Karmanos Cancer Institute (1) · ChemGenex Pharmaceuticals (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Novartis Pharmaceuticals (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · University of Nebraska (1) · Washington University School of Medicine (1)
United States (23) · Germany (1)
Scott R. Solomon, MD (2) · Adam R Craig, M.D., PhD (1) · Ann E. Woolfrey, MD (1) · Ann Woolfrey, MD (1) · Anthony Stein (1) · Bipin N. Savani, MD (1) · Daniel J. Weisdorf, MD (1) · Eunice Wang, MD (1) · Farhad Ravandi-Kashani (1) · Gunnar Ragnarsson (1) · Jeffrey Miller, MD (1) · John E. Wagner, MD (1) · Jorge Cortes (1) · Jorge Cortes, M.D. (1) · Jorge Cortes, MD (1)
P30CA015704 (2), N01CM17003 (1), N01CM62202 (1), P01CA018029 (1), P30CA016056 (1), P30CA016058 (1), P30CA022453 (1), P30CA036727 (1), R01AI053193 (1)